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Abstract
Background: Most of the randomized placebo-controlled trials that have examined the clinical
effects of multivitamin-mineral supplements on infection in the elderly have shown no significant
effect. The exceptions are three such trials, all using a supplement with the same composition, and
all claiming dramatic benefits: a frequently cited study published in 1992, which reported a 50%
reduction in the number of days of infection (NDI), and two 2002 replication studies. Questions
have been raised about the 1992 report; a second report in 2001 based on the same trial, but
describing effects of the supplement on cognitive functions, has been retracted by Nutrition. The
primary purpose of the present paper is to evaluate the claims about the effects of supplements on
NDI in the two replication reports.
Methods: Examination of internal consistency (outcomes of statistical tests versus reported data);
comparison of variability of NDI across individuals in these two reports with variability in other
trials; estimation of the probability of achieving the reported close agreement with the original
finding.
Results:  The standard deviations of NDI and levels of statistical significance reported are
profoundly inconsistent. The reported standard deviations of NDI are consistently below what
other studies have found. The reported percent reductions in NDI agree too closely with the
original study.
Conclusion: The claims of reduced NDI in the two replication reports should be questioned,
which also adds to concerns about the 1992 study. It follows that there is currently no trustworthy
evidence from randomized placebo-controlled clinical trials that favors the use of vitamin-mineral
supplements to reduce infection in the elderly.
Background
About 40% of the elderly in the United States take multi-
vitamin-mineral supplements [1], and their use is increas-
ing [2]. Studies of the clinical outcomes of such use
therefore have important health and economic implica-
tions, especially as the outcomes are expected to depend
on supplement constituent dosages. As shown in a recent
meta-analysis [3] by El-Kadiki and Sutton, studies that
examine the clinical effects of such supplements on the
health of the elderly have had sharply conflicting results.
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The studies they considered were randomized placebo-
controlled trials that examined the effects of multivita-
min-mineral supplements on infection in the elderly. In
most studies the participants were community-dwelling.
Five of the trials showed either negative or nonsignifi-
cantly positive effects, as did an additional trial of the
same type [4], published after their analysis. However,
dramatic benefits were reported in the three remaining
studies [5-7]. In each of these positive studies, which
lasted a full year, the number of days of infection (NDI)
in the supplement group was reported to be approxi-
mately half of the NDI in the placebo group. Averaged
over members of the supplement groups, this indicates
that the treatment reduced their NDI by about twenty days
during the treatment year. Especially given the growing
proportion of elderly in our population, the increasing
age of retirement, and the ballooning costs of health care,
such dramatic benefits would have enormous economic
and quality-of-life implications.
El-Kadiki and Sutton [3] considered several hypotheses
that might explain the conflict among the studies they
reviewed, including differences in supplement constitu-
ents. However, the meta-analysis did not take into
account the fact that the supplements in the three positive
studies had identical constituents and amounts, which
differed from those in the remaining studies. This identity
increases the plausibility of the hypothesis that differences
in supplement constituents are responsible for the con-
flict. An alternative possibility is that the claims in the pos-
itive reports are not to be trusted. Our purpose in the
present paper is to comment briefly on the validity of the
first of the positive reports [5], and to evaluate the other
two [6,7], which can be regarded as reporting successful
attempts to replicate the first. The possibility that trials
such as these may influence decisions about required die-
tary allowances increases the importance of assessing their
validity.
Results of the first of the positive trials were described in
two papers, one [5] in 1992 in The Lancet ("Report A"),
reporting the dramatic immunological effects described
above, the other [8] in 2001 in Nutrition, reporting greatly
improved cognitive functions. These papers have been
influential: they have together been cited more than 300
times; they were described in The New York Times [9]; and
they apparently led to the founding of a company [10] to
sell the supplement, for which the author holds a patent
[5,10,11]. However, we and others have questioned these
papers [12-16]. Problems we noted [13] in Report A [5]
include inequalities in an impossible direction for each of
six pairs of p values, SDs of NDI given in the text for both
treatment and placebo groups that are about three times
smaller than the values implied by histograms of NDI for
the two groups (but about twice as large as the implied
SEs), and the claim that all 96 individuals who were asked
agreed to participate. Another suspicious feature, discov-
ered recently, is that the number of observations in each
of the two histograms differs from the numbers of partic-
ipants in the two groups said to have completed the trial,
too few in one case, too many in the other. The more
numerous difficulties associated with the 2001 paper [8]
were deemed sufficiently serious by the editor of Nutrition
that he retracted it [17]. These difficulties in the 2001
paper add to our concern about Report A [5], and under-
line the importance of assessing the two replication stud-
ies.
The two papers reporting these replication studies
("Report B" [6] and "Report C" [7]) appeared together in
the January-February 2002 issue of Nutrition Research.
Along with 12 others of the 19 papers in that issue of the
journal, these two papers were accepted within one day of
being received, leaving little time for peer review. In what
follows we point out three problems with the findings in
both papers, problems of a similar kind.
First problem: means and variability measures inconsistent 
with p values
The 1992 study and the two replications measured effects
of the supplement by comparing supplement and placebo
groups. Information about NDI is presented in table 4 of
Report B [6] for three different time periods during the
study: the first six months, the second six months, and all
twelve months. Our table 1 presents those data. If we
assume that the means and standard deviations (SDs) in
this table are correct, and we use one tailed t tests, then,
for the three tests that correspond to the three columns of
the table, we get the first row of computed p values. Thus,
if the means and SDs in table 4 of Report B are correct, the
findings are much stronger than the reported p values
would indicate – indeed, so strong as to be unbelievable.
If the reported p values are correct, then we must question
the means, the SDs, or both.
Perhaps instead of reporting the SD in each case, as stated,
what is provided in Report B is actually the standard error
of the mean (SE). (The relation between these two quan-
tities is SE = SD/ , where n is the sample size.) When
we make this assumption (which would imply that the
data are far more variable), we get the second row of com-
puted p values in table 1. These p values are also smaller
than those reported, differing by as much as a factor of
4000.
Table 2 is based on table 1 of Report C [7] which includes
tests of three differences between the two groups. The
table also shows the results of our computations, done in
the same way as for table 1. Again there are dramatic
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inconsistencies and again, even if we assume that what
were reported as SDs were actually SEs, the p values we
calculated are much smaller than those reported, in this
case by as much as a factor of 2000. See Appendix 1 for
additional details.
Second problem: standard deviations inconsistent with 
other studies
One of the remarkable aspects of Reports B [6] and C [7]
is how closely the reported percentage effects on NDI
agree with results of the earlier study [5]. (See next sec-
tion.) To evaluate the likelihood of such agreement, we
need to know how variable NDI is across individuals. This
is one reason why it is important to determine whether
the SDs provided in Reports B and C could be as small as
claimed. To do so, we examined five other studies [18-22]
that reported the variability of NDI over individuals as
well as its mean.
Figure 1 shows that the SDs provided in Reports B and C
are an order of magnitude smaller than those reported in
the comparison studies. (The ratio of slopes of the top and
bottom fitted functions is 0.13/1.59 = 0.08.) If we assume
that what the authors called "SDs" were actually SEs, the
values in Reports B and C are still exceptionally small.
(The ratio of slopes of the top and middle functions is
0.56/1.59 = 0.35.)
Third problem: effect sizes too close to 1992 result
A third problem is the remarkably close agreement of the
findings about NDI in Reports B [6] and C [7] with those
in the original Report A [5]. All three papers report the
mean number of days of infection (mNDI) during twelve
months. These numbers, for placebo and supplement
groups, are provided in table 3, along with the percent
reduction in mNDI due to the supplement. The percent-
ages in the two replication reports differ by only +0.6%
and -0.3% from the percentage in the 1992 study. We
show in Appendix 3 that, given plausible assumptions,
the probability of such close agreement is less than 0.001,
a vanishingly small probability, which indicates that the
agreement of Reports B and C with Report A is too good
to be true.
Discussion
We have described three problems with the findings
described in Reports B [6] and C [7], that is, three reasons
to question these findings: First, the means and SDs of
NDI and the levels of statistical significance that they
report are profoundly inconsistent, and they remain
inconsistent even if what they reported as SDs were actu-
ally standard errors of the mean. Second, the SDs of NDI
that they report are more than ten times smaller than
those in a set of comparison studies; if what they reported
are standard errors of the mean, their SDs are about three
Table 2: Mean data and reported versus computed significance levels from Report C [7]
Illness Episodes Antibiotic Days Infection Days (mNDI)
Placebo Group (n = 18) 6.5 ± 1.0 58 ± 5 29 ± 4
Supplement Group (n = 18) 4.0 ± 0.7 27 ± 4 14 ± 2
Reported p values > 0.05 < 0.02 < 0.03
Computed p values
— Assuming "SD" = SD < 0.000000001 < 0.00000000000001 < 0.0000000000001
— Assuming "SD" = SE < 0.025 < 0.00001 < 0.001
Data are shown as mean ± SD. P values are the reported significance levels for statistical tests of the differences between placebo and supplement 
groups.
Table 1: Mean number of days of infection (mNDI) and reported versus computed significance levels from Report B [6]
First 6 months Second 6 months All 12 months
Placebo Group (n = 19) 12.7 ± 1.6 11.0 ± 1.2 23.7 ± 2.3
Supplement Group (n = 22) 8.5 ± 0.7 2.6 ± 0.3 11.1 ± 0.8
Reported p values < 0.05 < 0.004 < 0.02
Computed p values
— Assuming "SD" = SD < 0.0000000001 < 0.00000000000001 < 0.00000000000001
— Assuming "SD" = SE < 0.012 < 0.000001 < 0.0001
Data are shown as mean ± SD. P values are the reported significance levels for statistical tests of the differences between placebo and supplement 
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times smaller. Third, the probability that these two studies
could agree as well as they do with Report A is too small.
The finding of insufficient variability has been suggested
as a diagnostic for data fabrication [23,24].
A fourth problem with these findings is the fact that the
two studies share these three problems. The occurrence of
the same unusual features in both reports is surprising,
especially as neither author acknowledged help from the
other.
A fifth problem is that we have been unable to find Amrit
L. Jain, the author of Report C. His institutional address
("the Medical Clinic and Nursing Home, Jaipur, India") is
unverifiable; we were unable to find any trace of such a
place anywhere except in his paper; the mailing address
Table 3: Mean number of days of infection (mNDI) in three reports
Report Placebo Supplement Percent Reduction
Report A [5] 48 23 52.1%
Report B [6] 23.7 11.1 52.7%
Report C [7] 29 14 51.8%
Standard deviation versus mean of the number of days of infection (NDI) for Reports B [6] and C [7] compared with those of  five other studies Figure 1
Standard deviation versus mean of the number of days of infection (NDI) for Reports B [6] and C [7] compared with those of 
five other studies. Filled points, representing the data reproduced in tables 1 and 2, appear twice, with circles around them 
(assuming that the values reported as SDs were in fact SDs), and without circles (assuming that the values reported as SDs 
were SEs). Also shown are linear functions fitted by least squares to the data from the bronchitis groups (top fitted line, slope 
= 1.59), to the circled filled points (bottom fitted line, slope = 0.13), and to the uncircled filled points (middle fitted line, slope 
= 0.56). See Appendix 2 for more details.
Mean Number of Days of Infection, mNDI
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listed in his paper is a rented mailbox in Canada [15]. A
letter sent to that mailing address in 2002 that asked ques-
tions about his paper was not answered. All seven papers
that we found in Medline that might be authored by
someone with his name date from 1978 or earlier, and are
not in the fields of nutrition, aging, or infection.
A sixth problem is that in the author's reply [25] to our
criticisms [13] of his Report A [5] he mentioned neither of
these two replications [6,7] – an extraordinary oversight
because successful replications are among the best
defenses of a study against criticism.
Conclusion
In conclusion, problems associated with Reports B [6] and
C [7] of 2002, together with questions previously raised
[13] about Report A of 1992 [5] favor the conclusion from
Sutton and El-Kadiki's corrected meta-analysis [26] that
the trustworthy evidence indicates "no benefit" from the
use of multivitamin-mineral supplements for preventing
infection in the elderly.
Appendix 1: notes on tables 1 and 2
Report B [6] mentions several tests, but is not explicit
about which tests were used to obtain the reported p val-
ues. Because the variances may differ between supplement
and placebo groups, we computed p values by using the
more conservative t test provided by Cochran [27] some-
times called the "Welch modified two-sample t test",
which relaxes the assumption of equal variances. Because
this was a replication study, we calculated p values for one
tailed tests. (For two tailed tests these values must be dou-
bled.) Report C [7] says nothing about which tests were
used to determine significance levels. We therefore used
the same procedure as for Report B.
Appendix 2: choice of comparison studies for 
figure 1
The five comparison studies had group sizes ranging from
16 to 259, and covered periods of either five or six
months. We found them by searching the National
Library of Medicine's PubMed for articles with "days of ill-
ness" in the abstract. Because of possible distortion, we
did not use studies that reported the number of days of
sick leave from a job to estimate NDI. Also, we omitted
variability data from Report A [5] because of the large
inconsistencies between SD values stated in the text and
approximate SD values derived from the histograms [13],
and between the numbers of observations in the histo-
grams and the corresponding numbers of participants.
Because the SD increases with the mean in these data, we
have plotted the SDs versus the means in Figure 1. Also
plotted are corresponding data from Reports B [6] and C
[7]. These data are plotted twice, once assuming that what
were reported as SDs are in fact SDs, and once assuming
that they are SEs. Four of the five comparison studies [18-
21] involved individuals with chronic bronchitis rather
than normals. However, data from the fifth study [22],
involving normal seniors, suggest that for a given mean,
chronic bronchitis does not increase the variability of
NDI.
Sources of the comparison data are as follows: Points A
and B represent the number of exacerbation days during a
six-month period among two groups of people with
chronic bronchitis, measured by diary [18]. Points C and
D represent the same, measured by interview (table 4 of
[18]). Points E and F represent the number of days in bed
during a five-month period among two groups of patients
with chronic bronchitis complicated by severe airway
obstruction (table 5 of [19]). Points G and H represent the
number of days lost through illness during a six-month
period among two groups of patients with chronic bron-
chitis (table III of [20]). Points J and K represent the
number of days sick during a six-month period among
two groups of patients with chronic obstructive pulmo-
nary disease (table 2 of [21]). Points L and M represent the
number of days with upper respiratory tract infection dur-
ing a six month period among two groups of normal sen-
iors (Fig. 1 of [22] and Steven M. Wood, personal
communication, July 16, 2004).
Because NDI is non-negative, mNDI = 0 implies that
SD(NDI) = 0; hence the linear functions fitted to the data
were forced to pass through the origin. (However, even
without this constraint the three fitted y values at x = 0 dif-
fer from zero by no more than one unit.)
Appendix 3: estimation of probability of the 
claimed good agreement
Assuming that the trials described in Reports B [6] and C
[7] were conducted and reported independently, how
likely is the close agreement shown in table 3? This
depends on the variability of mNDI: the greater the varia-
bility, the less likely the agreement. Unfortunately, as
noted above, the different sources of information about
variability (p values and SDs) within each of Reports B
and C are inconsistent. Thus, to estimate the probability
that the percentage in each replication report would agree
as well as it did with the percentage in Report A [5], we
assumed that the reported means (mNDIs) are correct,
and made three different assumptions about variability to
obtain estimates of the variances of the mNDIs. Because
the assumption that the reported variability measures
were in fact SDs led to the implausible significance levels
shown in tables 1 and 2, and because of their great diver-
gence from SDs in other studies (Fig. 1), we have not con-
sidered this possibility.Nutrition Journal 2006, 5:30 http://www.nutritionj.com/content/5/1/30
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According to Assumption 1, what were called "SDs" in the
replication reports were actually correct values for the SEs.
The variance of mNDI, var(mNDI), is SE2.
According to Assumption 2, the relation between SD and
mean is given by the top fitted line in Figure 1: SD = 1.59
× Mean, the line fitted to the data from the bronchitis
groups. (This seems more plausible than Assumption 1.)
Thus we used this equation with the mNDI values
reported in Reports B and C to estimate the SDs, and from
these and the sample sizes, var(mNDI).
According to Assumption 3, the reported significance lev-
els are correct. However, whereas we need exact p values,
we are given only upper bounds (p < 0.03 for Report B, p
< 0.02 for Report C). We therefore used the next smaller p
value (p = 0.02 for Report B, p = 0.01 for Report C), bias-
ing the result towards higher probabilities of close agree-
ment. Assuming that the p values were obtained from one
tailed t tests, this enabled us to estimate the SEs, and from
these, the values of var(mNDI). We obtained these SE esti-
mates using three different methods, and report results
from the method that produced the highest probabilities
of agreement. The three methods were: (a) Conventional
t test, assuming that the true SDs differ from those
reported by a common factor; (b) Conventional t test,
assuming that the true SDs are equal; (c) Welch modified
two-sample t test, assuming that the true SDs differ from
those reported by a common factor. Because of the bias
mentioned above, the estimated probabilities of close
agreement based on Assumption 3 are upper bounds.
Estimation of the probability also requires us to assume
the form of the distribution of mNDI; we made our esti-
mates assuming both Gaussian and gamma distributions
consistent with the reported means and with the inferred
values of of var(mNDI). For each of the two replication
studies and each assumption, the desired probability was
estimated as follows. Given the mean, inferred variance,
and assumed distributional form of mNDI for the supple-
ment and placebo groups of subjects in that study, we gen-
erated a sample of 1,000,000 pairs of mNDI values
(mNDIs for the supplement group and mNDIp for the pla-
cebo group). Next, we obtained the ratio of the two num-
bers in each pair, (mNDIs/mNDIp). We then determined
what proportion of these values were at least as close to
the original finding as the observed value.
The probability that both of two independent replication
studies would agree at least as well as they did with the
original is the product of their separate probabilities. It is
therefore the product of these two proportions, one for
each replication study, that gives us the estimated proba-
bility. Under Assumption 1, the estimated probabilities
for Gaussian and gamma distributions are 0.00203 and
0.00204, respectively; under Assumption 2 they are both
0.00019; and under Assumption 3 the upper bounds are
0.00066 and 0.00065, respectively.
Even under Assumption 1, which is implausible given the
variability of NDI in other studies shown in Figure 1, the
means and variabilities of these two sets of data make the
observed closeness of agreement extremely unlikely.
Under both of the other assumptions the chance of such
good agreement is vanishingly small: too good to be true.
These results also show that our conclusion is insensitive
to the choice of distribution.
Competing interests
We are the authors of a letter [15] in Nutrition criticizing
the 2001 paper [8] on cognitive effects, and co-authors of
a letter [13] in The Lancet criticizing Report A [5] based on
the same trial.
Authors' contributions
Both authors are responsible for the reasoning in the
paper. SS carried out the computations and wrote the first
draft. SR obtained the data for the mean and SD of NDI
from the five other studies, and provided editorial com-
ments. Both authors read and approved the final manu-
script.
Acknowledgements
We thank Allen Osman and Alan Shenkin for helpful discussion, and Steven 
M. Wood and Bobbi Langkamp-Henken for furnishing unpublished details 
of their data [22]. We also thank Anna Baumgaertel, Michael Meguid, and 
Jennifer Sternberg for helpful comments on the manuscript.
References
1. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF:
Dietary supplement use by US Adults: Data from the
national health and nutrition examination survey 1999–2000.
Am J Epidemiol 2004, 160:339-349.
2. Millen AE, Dodd KW, Subar AF: Use of vitamin, mineral, nonvi-
tamin, and nonmineral supplements in the United States:
the 1987, 1992, and 2000 national health interview survey
results.  J Am Diet Assoc 2004, 104:942-950.
3. El-Kadiki A, Sutton AJ: Role of multivitamins and mineral sup-
plements in preventing infections in elderly people: system-
atic review and meta-analysis of randomised controlled
trials.  BMJ 2005, 330:871-876.
4. Avenell A, Campbell MK, Cook JA, Hannaford PC, Kilonzo MM,
McNeill G, Milne AC, Ramsay CR, Seymour DG, Stephen AI, Vale LD:
Effect of multivitamin and multimineral supplements on
morbidity from infections in older people (MAVIS trial):
pragmatic, randomised, double blind, placebo controlled
trial.  BMJ 2005, 331:324-329.
5. Chandra RK: Effect of vitamin and trace-element supplemen-
tation on immune responses and infection in elderly sub-
jects.  Lancet 1992, 340:1124-7.
6. Chandra RK: Influence of multinutrient supplement on
immune responses and infection-related illness in 50–65 year
old individuals.  Nutr Res 2002, 22:5-11.
7. Jain AL: Influence of vitamins and trace-elements on the inci-
dence of respiratory infection in the elderly.  Nutr Res 2002,
22:85-87.
8. Chandra RK: Effect of vitamin and trace-element supplemen-
tation on cognitive function in elderly subjects.  Nutrition 2001,
17:709-712.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Nutrition Journal 2006, 5:30 http://www.nutritionj.com/content/5/1/30
Page 7 of 7
(page number not for citation purposes)
9. Brody JE: Nutrition a key to better health for elderly.  New York
Times . August 21, 2001
10. White C: Three journals raise doubts on validity of Canadian
studies.  BMJ 2004, 328:67. Corrections in BMJ 2004;328:257
11. Chandra RK: Graying of the immune system. Can nutrient
supplements improve immunity in the elderly?  JAMA 1997,
277:1398-9.
12. Shenkin SD, Whiteman MC, Alison P, Deary IJ: Supplementation
and the elderly: dramatic results?  Nutrition 2002, 18:364.
13. Carpenter KC, Roberts S, Sternberg S: Nutrition and immune
function: a 1992 report.  Lancet 2003, 361:2247.
14. Meguid MM, Shenkin A: Introduction: Nutritional supplements
and the quest to improve human performance – the need for
the strictest standards and rigor when reporting clinical tri-
als.  Nutrition 2003, 19:955-956.
15. Roberts S, Sternberg S: Do nutritional supplements improve
cognitive function in the elderly?  Nutrition 2003, 19:976-978.
16. Shenkin SD, Whiteman MC, Alison P, Deary IJ: Continued concern
about nutritional supplements and cognitive function in the
elderly.  Nutrition 2004, 20:336.
17. Meguid MM: Retraction.  Nutrition 2005, 21:286.
18. Ekberg-Jansson A, Larson M, MacNee W, Tunek A, Wahlgren L,
Wouters EF, Larsson S: N-isobutyrylcysteine, a donor of sys-
temic thiols, does not reduce the exacerbation rate in
chronic bronchitis.  Eur Respir J 1999, 13:829-34.
19. British Thoracic Society Research Committee: Oral N-acetyl-
cysteine and exacerbation rates in patients with chronic
bronchitis and severe airways obstruction.  Thorax 1985,
40:832-5.
20. Olivieri D, Zavattini G, Tomasini G, Daniotti S, Bonsignore G, Ferrara
G, Carnimeo N, Chianese R, Catena E, Marcatili S, Del Donno M,
Grassi C, Pozzi E, Grassi V, Tantucci C, Lucchesi M, Schimid G, Mar-
chioni CF, Penitenti S, Mistretta A, Crimi N, Casali L, Cabiddu R, Don-
ner C, Patessio A, Massei V, Sanguinetti CM, Orlandi O, Bruna S,
Serra C, Giacopelli A: Ambroxol for the prevention of chronic
bronchitis exacerbations: long-term multicenter trial. Pro-
tective effect of ambroxol against winter semester exacer-
bations: a double-blind study versus placebo.  Respiration 1987,
51:42-51.
21. Pela R, Calcagni AM, Subiaco S, Isidori P, Tubaldi A, Sanguinetti CM:
N-acetylcysteine reduces the exacerbation rate in patients
with moderate to severe COPD.  Respiration 1999, 66:495-500.
22. Langkamp-Henken B, Bender BS, Gardner EM, Herrlinger-Garcia KA,
Kelley MJ, Murasko DM, Schaller JP, Stechmiller JK, Thomas DJ,
Wood SM: Nutritional formula enhanced immune function
and reduced days of symptoms of upper respiratory tract
infection in seniors.  J Am Geriatr Soc 2004, 52:3-12.
23. Evans S: Statistical aspects of the detection of fraud.  In Fraud
and misconduct in medical research 3rd edition. Edited by: Lock S, Wells
F, Farthing M. London: BMJ Publishing Group; 2001:186-204. 
24. Al-Marzouki S, Evans S, Marshall T, Roberts I: Are these data real?
Statistical methods for the detection of data fabrication in
clinical trials.  BMJ 2005, 331:267-270.
25. Chandra RK: Author's reply.  Lancet 2003, 361:2247-8.
26. El-Kadiki A, Sutton AJ: Correction.  BMJ 2005, 331:142.
27. Cochran WC: Approximate significance levels of the Behrens-
Fisher test.  Biometrics 1964, 20:191-195.